Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study of ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT07601425 is registered in ClinicalTrials.gov with Atavistik Bio, Inc as lead sponsor.

NCT NCT07601425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07601425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study of ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Lead sponsor
Atavistik Bio, Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
July 27, 2026
Completion date
March 31, 2030
Enrollment
100 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia (hht), osler weber rendu disease